2023 World Conference on Lung Cancer (Posters)-EP08.02. Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

EP08.02. Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) - PDF(Slides)

Back to course

Pdf Summary

This study evaluated the real-world survival outcomes and post-progression therapy of patients with stage III non-small cell lung cancer (NSCLC) who underwent chemoradiotherapy (CRT) and consolidation Durvalumab. The study aimed to assess whether these real-world outcomes matched the clinical trial data. The researchers conducted a retrospective review of electronic medical records from June 2017 to December 2021. They analyzed baseline characteristics, progression-free survival (PFS), overall survival (OS), and first site of relapse in patients who progressed following Durvalumab.<br /><br />The baseline characteristics of the patients were similar to those in the PACIFIC trial, which established consolidation immunotherapy as standard care for stage III NSCLC. The median follow-up was 23 months, and 56% of patients progressed, with 34% dying and 20% discontinuing Durvalumab due to adverse events. The study found that the median OS was 43.7 months, and the median PFS was 22.3 months.<br /><br />The first site of relapse in patients who progressed following Durvalumab was intracranial in 23% of cases, extra thoracic in 32%, and intrathoracic in 45%. Further analysis examined PFS after first-line therapy, and the results varied depending on the treatment received.<br /><br />The study concluded that 80% of the real-world population did not meet the criteria from the PACIFIC trial regarding the timing of Durvalumab initiation after CRT. Despite this, there was an improvement in overall survival in stage III NSCLC at the institution compared to the historical control after the introduction of Durvalumab. The study demonstrated comparable survival outcomes to the PACIFIC trial, even though the majority of patients were treated outside the trial criteria.<br /><br />The researchers recommended further prospective data to evaluate predictive factors that could improve patient selection for Durvalumab and maximize its benefits while minimizing toxicity. Overall, this study provides insights into the real-world experience of survival outcomes in patients with unresectable stage III NSCLC who received consolidation Durvalumab after CRT.

Asset Subtitle

Nicole Pringle

Meta Tag

Speaker Nicole Pringle

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

stage III non-small cell lung cancer

chemoradiotherapy

consolidation Durvalumab

real-world survival outcomes

post-progression therapy

clinical trial data

electronic medical records

progression-free survival

overall survival

first site of relapse